Strategic emphasis on D2C e-commerce growth

Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 2208, Dunedin 9012, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz




26 March 2021

Strategic emphasis on D2C e-commerce growth
Following the announcement of the launch of our breakthrough cosmetic skincare offering on 23
March 2021, we are pleased to update the market regarding our strategic emphasis on revenue
opportunities through the D2C e-commerce channel.
As previously advised, over the past 12 months our existing retail sales channels have been impacted
by the covid pandemic with a reduction in foot traffic through retail stores and a trend toward online
purchase.
In line with this trend, we continue to build our own internal e-commerce capability and strategic
partnerships to transition the business towards a D2C business model, emphasising a digital e-
commerce strategy supported by distribution partnerships which complement Blis’ own in-market
activities.
Notable recent e-commerce developments which are expected to make a meaningful contribution
to future revenue growth include:
• In January 2021, Blis launched the BLIS PROBIOTICS® store on Alibaba’s TMall Global
marketplace, the largest cross-border marketplace in China. This represents the next stage
of the company’s CBEC strategy.
• In Canada we recently launched our products on Amazon. This activity will be
complemented by retail pharmacy and health store activity with our distribution partner
Purity Life Health Products. We have now supplied the first shipment for pharmacy
distribution.
• More recently we announced the launch of our new breakthrough skincare product under
the Unconditional Skincare Co brand. The live probiotic hydration serum will initially be sold
exclusively on our own ecommerce platform www.unconditionalskin.com
. The next phase of
the launch includes a media and influencer event mid April 2021, followed by an extensive
promotional campaign.
Along with the launch of our first skincare product, we have an exciting pipeline of products in
development including a probiotic toothpaste, additional upper respiratory health / immunity offers
and skin and personal care products.
Our ongoing ability to develop and commercialise unique probiotic offerings is underpinned by a
substantial proprietary library of probiotic strains. The genomic sequencing and assessment of this
extensive library provides the catalyst for future opportunities. Along with this we will continue to
explore additional applications for our existing probiotic strains including functional foods, pet care,
extraction of peptides and virus/ immunity solutions.
The company continues to build and protect a range of IP assets including patents, trademarks,
trade secrets, clinical data and information to support regulatory approvals. BLIS® probiotic strains
are supported by decades of research and know-how covering fermentation, characterisation,

Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 2208, Dunedin 9012, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
validation, quality control and formulation. Extensive dossiers have been built up covering this
information that support regulatory approvals and represent barriers to competitive entry.
The company has an established brand in market and has a programme of ongoing IP development
including new patent opportunities. Additional patents in process include a new oral composition, a
new use against respiratory infections, new fermentation formulations of BLIS K12™ and BLIS M18™,
and new topical composition and use.
In the new financial year ahead we will be focused on growing sales of the existing portfolio across
our 3 attractive health and wellness categories ENT/immunity, oral health and skincare, while also
continuing to develop new innovative probiotic offerings to take to market.

Ends

For further information, please contact:

Brian Watson
CEO
+64 27 705 9133


About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with
evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific
health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS
products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information about Blis
Technologies Ltd can be found at www.blis.co.nz.


Website: www.unconditionalskin.com
Instagram: @unconditionalskin #BLISQ24 #USC
Facebook: @unconditionalskin